TRDA — Entrada Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1689375 ·
Last close
$4.96
Market Cap
$194.19M
52W High
$16.45
52W Low
$4.11
ADV30
471,289
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 898,000 | — | -44,963,000 | -42,763,000 | 298,877,000 | 99,280,000 | 65,466,000 |
| Mar 2026 | 875,000 | — | -42,303,000 | -39,717,000 | 335,518,000 | 76,444,000 | 64,664,000 |
| Dec 2025 | 1,299,000 | — | -42,208,000 | -39,164,000 | 377,378,000 | 90,394,000 | 71,245,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-134,674,000
Investing CF
$160,164,000
Financing CF
$650,000
CapEx
$-1,474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.84
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-355,574,000
Inventory
—
Receivables
$816,000
ST Investments
$123,725,000
EBIT TTM
$-176,525,000
Pretax Income TTM
$-164,959,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,686,000
EBITDA
$-170,863,008
Free Cash Flow
$-77,671,624
Enterprise Value
$7,987,339
Total Cash
$223,004,992
Total Debt
$48,544,000
Shares Out
39,150,334
Trailing EPS
$-3.84
Book Value
$8.50
ROE
-54.1%
ROA
-29.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 25,421,000 | -157,898,000 | -143,750,000 | 377,378,000 | 71,245,000 | 306,133,000 | -128,512,000 |
| Dec 2024 | 210,782,000 | 47,011,000 | 65,626,000 | 526,321,000 | 97,643,000 | 428,678,000 | -41,557,000 |
| Dec 2023 | 129,013,000 | -3,162,000 | -6,685,000 | 469,192,000 | 226,832,000 | 242,360,000 | 139,803,000 |
| Dec 2022 | 0 | -97,248,000 | -94,616,000 | 252,056,000 | 39,502,000 | 212,554,000 | -93,786,000 |
TTM Snapshot
Revenues TTM
$4,686,000
NetIncome TTM
$-165,778,000
OpCashFlow TTM
—
Assets (Latest)
$298,877,000
Forward EPS
$-3.20
Max Pain — expiry 2026-12-18
max pain strike: $5.00 · spot: $5.03 · call oi: 5,102 · put oi: 79
Expected Move to 2026-12-18:
±$2.13
(42.35%) —
implied range
$2.90 –
$7.16
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SIGA | SIGA TECHNOLOGIES INC | $196.16M | $2.73 | — |
| ADCT | ADC Therapeutics SA | $189.89M | $1.35 | — |
| VOGX | Vogenx, Inc. | $200.25M | $13.48 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $201.25M | $20.51 | — |
| RNAC | Cartesian Therapeutics, Inc. | $186.68M | $6.12 | — |
News headlines (Yahoo Finance, 1h cache)
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
2026-11-18 08:00 · Yahoo
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 13:35 · Yahoo
Entrada Therapeutics Reports Third Quarter 2026 Financial Results
2026-11-05 12:00 · Yahoo
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
2026-10-21 11:00 · Yahoo
What's Going On With Entrada Therapeutics Stock Wednesday?
2026-10-14 16:47 · Yahoo
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
2026-10-14 11:00 · Yahoo
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
2026-10-14 11:00 · Yahoo
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
2026-09-10 11:00 · Yahoo
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 20:30 · Yahoo
Entrada’s stock drops as DMD drug’s efficacy falls short
2026-05-08 10:39 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.